Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL14655665

CCc1ccc(-c2ccccc2)nc1.O=S(=O)(O)C(F)(F)F.[Ir]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
CYP11B1 P15538 11/20 0.45
CYP11B2 P19099 11/20 0.45
TP53 P04637 2/20 0.43
CHRM5 P08912 1/20 0.43
CYP3A4 P08684 1/20 0.42
LDHA P00338 1/20 0.41
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
BAZ2B Q9UIF8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL29770051 0.86 NPC1 (0.51) NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2
Trifluoromethanesulfonic Acid SCHEMBL14655667 0.86 NPC1 (0.51) NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2
Trifluoromethanesulfonic Acid SCHEMBL14655666 0.86 NPC1 (0.51) NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2
SCHEMBL146559 0.82 NPC1 (0.65) NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2
Trifluoromethanesulfonic Acid SCHEMBL14655806 0.82 CYP3A4 (0.50) NPC1RAB9ACYP11B1CYP11B2CYP3A4
SCHEMBL27891018 0.81 NPC1 (0.56) NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL28148550 0.81 NPC1 (0.63) NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2
Trifluoromethanesulfonic Acid SCHEMBL14655584 0.80 LOXL2 (0.40) RAB9ASMN1; SMN2TP53CYP3A4
SCHEMBL152870 0.79 NPC1 (0.66) NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2
Trifluoromethanesulfonic Acid SCHEMBL14655479 0.78 FFAR1 (0.44) RAB9ACYP11B1CYP11B2TP53LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240138251-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS UNIVERSAL DISPLAY CORPORATION (US) 2024-04-25 US disclosed
US-11910700-B2 Heteroleptic iridium complexes as dopants UNIVERSAL DISPLAY CORPORATION (US) 2024-02-20 US disclosed
US-20220302396-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS UNIVERSAL DISPLAY CORPORATION (US) 2022-09-22 US disclosed
US-11380854-B2 Heteroleptic iridium complexes as dopants UNIVERSAL DISPLAY CORPORATION (US) 2022-07-05 US disclosed
US-20190245153-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS UNIVERSAL DISPLAY CORPORATION (US) 2019-08-08 US disclosed
US-10312458-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2019-06-04 US disclosed
US-20160099425-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS UNIVERSAL DISPLAY CORPORATION 2016-04-07 US disclosed
US-9184397-B2 Heteroleptic iridium complexes as dopants UNIVERSAL DISPLAY CORPORATION (US) 2015-11-10 US disclosed
EP-2551933-B1 Heteroleptic iridium complexes as dopants UNIVERSAL DISPLAY CORP (US) 2014-09-24 EP disclosed
US-20140159028-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS UNIVERSAL DISPLAY CORPORATION (US) 2014-06-12 US disclosed
US-8709615-B2 Heteroleptic iridium complexes as dopants UNIVERSAL DISPLAY CORPORATION (US) 2014-04-29 US disclosed
US-20130026452-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS UNIVERSAL DISPLAY CORPORATION (US) 2013-01-31 US disclosed
EP-2551933-A1 Heteroleptic iridium complexes as dopants Universal Display Corporation (US) 2013-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160099425-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885
US-20140159028-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885
US-20190245153-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885
US-10312458-B2 Organic electroluminescent materials and devices JUND, OCIAD1, OCIAD2 NPC1 1062/4885RAB9A 2128/4885SMN1; SMN2 3567/4885
US-20240138251-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885
US-20130026452-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885
US-11380854-B2 Heteroleptic iridium complexes as dopants JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885
US-11910700-B2 Heteroleptic iridium complexes as dopants JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885
US-20220302396-A1 HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS JUND, DRD2, DRD1 NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.